International Clinical Research Center, Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, WA, United States; Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, United States; Division of Allergy and Infectious Diseases, Department of Medicine, School of Medicine, University of Washington, Seattle, WA, United States.
International Clinical Research Center, Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, WA, United States; Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, United States.
J Clin Virol. 2023 Apr;161:105420. doi: 10.1016/j.jcv.2023.105420. Epub 2023 Mar 3.
Guidelines for SARS-CoV-2 have relied on limited data on duration of viral infectiousness and correlation with COVID-19 symptoms and diagnostic testing.
We enrolled ambulatory adults with acute SARS-CoV-2 infection and performed serial measurements of COVID-19 symptoms, nasal swab viral RNA, nucleocapsid (N) and spike (S) antigens, and replication-competent SARS-CoV-2 by viral growth in culture. We determined average time from symptom onset to a first negative test result and estimated risk of infectiousness, as defined by positive viral growth in culture.
Among 95 adults, median [interquartile range] time from symptom onset to first negative test result was 9 [5] days, 13 [6] days, 11 [4] days, and >19 days for S antigen, N antigen, culture growth, and viral RNA by RT-PCR, respectively. Beyond two weeks, virus growth and N antigen titers were rarely positive, while viral RNA remained detectable among half (26/51) of participants tested 21-30 days after symptom onset. Between 6-10 days from symptom onset, N antigen was strongly associated with culture positivity (relative risk=7.61, 95% CI: 3.01-19.22), whereas neither viral RNA nor symptoms were associated with culture positivity. During the 14 days following symptom onset, the presence of N antigen remained strongly associated (adjusted relative risk=7.66, 95% CI: 3.96-14.82) with culture positivity, regardless of COVID-19 symptoms.
Most adults have replication-competent SARS-CoV-2 for 10-14 after symptom onset. N antigen testing is a strong predictor of viral infectiousness and may be a more suitable biomarker, rather than absence of symptoms or viral RNA, to discontinue isolation within two weeks from symptom onset.
SARS-CoV-2 指南依赖于有限的数据,这些数据涉及病毒传染性的持续时间以及与 COVID-19 症状和诊断检测的相关性。
我们招募了患有急性 SARS-CoV-2 感染的门诊成年人,并对 COVID-19 症状、鼻拭子病毒 RNA、核衣壳 (N) 和刺突 (S) 抗原以及通过病毒培养进行复制型 SARS-CoV-2 的连续测量。我们确定了从症状发作到第一次阴性检测结果的平均时间,并根据培养中阳性病毒生长来估计传染性风险。
在 95 名成年人中,从症状发作到第一次阴性检测结果的中位数[四分位距]时间分别为 S 抗原、N 抗原、培养生长和 RT-PCR 检测病毒 RNA 的 9[5]天、13[6]天、11[4]天和>19 天。超过两周后,病毒生长和 N 抗原滴度很少呈阳性,而在症状发作后 21-30 天接受检测的一半(26/51)参与者的病毒 RNA 仍可检测到。在症状发作后 6-10 天,N 抗原与培养阳性高度相关(相对风险=7.61,95%CI:3.01-19.22),而病毒 RNA 或症状与培养阳性均不相关。在症状发作后 14 天内,无论 COVID-19 症状如何,N 抗原的存在仍与培养阳性高度相关(调整后的相对风险=7.66,95%CI:3.96-14.82)。
大多数成年人在症状发作后 10-14 天仍具有复制型 SARS-CoV-2。N 抗原检测是病毒传染性的有力预测指标,而不是无症状或病毒 RNA 缺失,可作为从症状发作开始两周内停止隔离的更合适的生物标志物。